Statistiche di base
| CIK | 1783036 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NLS Pharmaceutics AG
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive off |
|
| September 4, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2025 Commission file number: 001-39957 NLS PHARMACEU |
|
| September 4, 2025 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients - Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United States and India - Hong Kong represents a meaningful diabetes market and a critical gateway into Mainland China—including the Greater Bay Area—s |
|
| September 3, 2025 |
Exhibit 4.2 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT by and between NLS PHARMACEUTICS LTD., and VSTOCK TRANSFER, LLC, as the Rights Agent Dated as of [*], 2025 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated [*], 2025 (the “Signing Date”), is by and between, NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“NLS”), and VStock Transfer, LLC, a California limited liabi |
|
| September 3, 2025 |
As filed with the U.S. Securities and Exchange Commission on September 3, 2025. As filed with the U.S. Securities and Exchange Commission on September 3, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 7 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdicti |
|
| August 29, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 3) Commission file number: 001-39957 N |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal e |
|
| August 29, 2025 |
SEVENTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 SEVENTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Seventh Amendment to Agreement of Merger and Plan of Reorganization (this “Amendment”) is made and entered into as of August 29, 2025, by and among Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “Company”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerlan |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal e |
|
| August 6, 2025 |
Exhibit 99.1 Execution Version EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (this “Agreement”), dated as of August 5, 2025, is entered into by and between NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”) and Alpha Capital Anstalt (the “Holder”). RECITALS WHEREAS, the Holder is the holder of a warrant dated October 10, 2024, to purchase 207,913 shares o |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive office |
|
| July 29, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 29, 2025. As filed with the U.S. Securities and Exchange Commission on July 29, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction o |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| July 18, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 4) Commission file number: 001-39957 NLS |
|
| July 18, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 18, 2025. As filed with the U.S. Securities and Exchange Commission on July 18, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction o |
|
| July 18, 2025 |
SIXTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 SIXTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Sixth Amendment to Agreement of Merger and Plan of Reorganization (this “Amendment”) is made and entered into as of July 18, 2025, by and among Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “Company”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“Pa |
|
| July 17, 2025 |
Exhibit 99.1 NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the need for life-long immuno |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) |
|
| July 1, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2025 Commission file number: 001-39957 NLS PHARMACEUTICS |
|
| July 1, 2025 |
FIFTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 FIFTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Fifth Amendment to Agreement of Merger and Plan of Reorganization (this “Amendment”) is made and entered into as of July 1, 2025, by and among Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “Company”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“Par |
|
| June 30, 2025 |
Exhibit 99.6 NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, Switzerland, June 30, 2025 – NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system ( |
|
| June 30, 2025 |
AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT Exhibit 99.2 AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT This Amendment to the Securities Purchase Agreement (this “Amendment”) is dated as of June 26, 2025, among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”) and the purchasers identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and col |
|
| June 30, 2025 |
Exhibit 99.4 June 26, 2025 Alpha Capital Anstalt Altenbach 8 9490 Vaduz, Liechtenstein Ladies and Gentlemen: Reference is made to that certain Securities Purchase Agreement, dated as of March 26, 2025 (the “Purchase Agreement”), by and among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and including any successor Company thereto (the “Company”) and each of the o |
|
| June 30, 2025 |
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 99.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 23, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 23, 2025. As filed with the U.S. Securities and Exchange Commission on June 23, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction o |
|
| June 16, 2025 |
NLS Pharmaceutics CEO Issues Letter to Shareholders Exhibit 99.1 NLS Pharmaceutics CEO Issues Letter to Shareholders ZURICH, June 16,2025 /PRNewswire/ - NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders. Dear Shareholders, We are delighted to share a summary of NLS Pharmaceutics’ achi |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 16, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 (Report No. 3) Commission file number: 001-39957 NLS |
|
| June 10, 2025 |
[voting instructions and appendices follow] Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, June 6, 2025 Invitation to the Ordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invite you to |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 (Report No. 2) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 9, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 9, 2025. As filed with the U.S. Securities and Exchange Commission on June 9, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction of |
|
| June 9, 2025 |
PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 4.1 PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Warrant Shares: [] Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, [] or its assigns (the “Holder”) |
|
| June 9, 2025 |
Exhibit 10.36 July 17, 2024 (“Effective Date”) Kadimastem Ltd. Pinchas Sapir 7, Weizmann Science Park Nes-Ziona, Israel For the attention of: Executive Chairman & President Dear Mr. Twito, Agreement for the provision of Manufacturing services Kadimastem (TASE: KDST) (“Client”) is a bio-pharmaceutical company developing regenerative medicine therapies derived from Human Embryonic Stem Cells (hESCs) |
|
| June 6, 2025 |
FOURTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 FOURTH AMENDMENT TO AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Fourth Amendment to Agreement of Merger and Plan of Reorganization (this “Amendment”) is made and entered into as of June 5, 2025, by and among Kadimastem Ltd., an Israeli publicly traded company limited by shares (the “Company”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“P |
|
| June 6, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-39957 NLS PHARMACEUTICS |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by NLS Pharmaceutics Ltd. (the “Company”), the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies with the requirem |
|
| May 16, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (File Nos. 333-284696, 333-284811, 333-282788, 333-262489, 333-268690 and 333-269220) of NLS Pharmaceutics Ltd. of our report dated May 15, 2024, except for the effects of the reverse share split discussed in Note 2 to the consolidated |
|
| May 16, 2025 |
Description of Rights of Each Class of Securities Exhibit 2.1 Description of Rights of Each Class of Securities Type and Class of Securities As part of the initial public offering of the NLS Pharmaceutics Ltd., or the Company, in February 2021 on the Nasdaq Capital Market, the Company conducted a share capital increase. As of February 5, 2021, the Company had a registered share capital of CHF 235,826.50 divided into 11,791,325 registered shares w |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Nicole Fernandez-McGovern, certify that: 1. I have reviewed this annual report on Form 20–F of NLS Pharmaceutics Ltd.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumst |
|
| May 16, 2025 |
Exhibit 11(b) NLS PHARMACEUTICS LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: January 1st, 2024 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related individuals of NLS Pharmaceutics Ltd., a Swiss corporation (the “Company”), with respect to transactions in the Company’s secur |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2024 (the “Report”) by NLS Pharmaceutics Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies with the requ |
|
| May 16, 2025 |
AMENDMENT NO. 2 TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 4.28 AMENDMENT NO. 2 TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Amendment is made as of February 17, 2025 (this “Amendment”) to the Agreement of Merger and Plan of Reorganization, dated November 4, 2024 (as previously amended on January 30, 2025, the “Agreement”), between Kadimastem Ltd., an Israeli publicly traded company limited by shares (“Kadimastem”), NLS Pharmaceutics |
|
| May 16, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Alexander Zwyer, certify that: 1. I have reviewed this annual report on Form 20–F of NLS Pharmaceutics Ltd.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde |
|
| May 16, 2025 |
FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| May 16, 2025 |
Independent Registered Public Accounting Firm’s Consent Exhibit 15.2 Independent Registered Public Accounting Firm’s Consent We consent to the incorporation by reference in the Registration Statement of NLS Pharmaceutics Ltd. On Forms F-3 (File Nos. 333-284696, 333-284811, 333-282788, 333-262489, 333-268690 and 333-269220) of our report dated May 16, 2025, with respect to our audit of the consolidated financial statements of NLS Pharmaceutics Ltd. for |
|
| May 5, 2025 |
AMENDMENT NO. 3 TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 AMENDMENT NO. 3 TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Amendment is made as of May 5, 2025 (this “Amendment”) to the Agreement of Merger and Plan of Reorganization, dated November 4, 2024 (as previously amended on January 30, 2025 and on February 17, 2025, the “Agreement”), between Kadimastem Ltd., an Israeli publicly traded company limited by shares (“Kadimastem”) |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) |
|
| May 1, 2025 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: . . . . . 3235-0058 Washington, D.C. 20549 Expires: May 31, 2025 Estimated average burden hours FORM 12b-25 per response. . . . . . . . 2.50 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39957 CUSIP NUMBER H57830137 (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Perio |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal ex |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices |
|
| April 15, 2025 |
Exhibit 99.1 NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl- Induced Reward in Animal Models Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics Favorable results support potential expansion into high-value markets beyond ADHD and narcolepsy Zurich, Switzerland – April 15, 2025 – NLS Phar |
|
| April 15, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2025 Commission file number: 001-39957 NLS PHARMACEUTICS |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A (Amendment No. 1) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Add |
|
| April 4, 2025 |
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 99.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 31, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 31, 2025. As filed with the U.S. Securities and Exchange Commission on March 31, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal ex |
|
| March 31, 2025 |
Exhibit 99.5 NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement The equity financing is at a 10% premium to the market share price1 ZÜRICH, Switzerland, March 31, 2025 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for ce |
|
| March 31, 2025 |
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 26, 2025, by and among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland, with headquarters located at The Circle 6, 8058 Zurich, Switzerland (the “Company”), and the investors listed on the Schedule of Purchasers attached hereto (each, a “Purchaser” and col |
|
| March 31, 2025 |
Exhibit 10.13 LICENCE AGREEMENT by and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED and KADIMASTEM LIMITED August 31, 2009 Ref.: 05-2753-09-18 No.: 113177-004 LICENCE AGREEMENT Between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, “Yeda”) and KADIMASTEM LIMITED a company duly registered u |
|
| March 31, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 (Report No. 2) Commission file number: 001-39957 NL |
|
| March 31, 2025 |
PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES NLS PHARMACEUTICS LTD. Exhibit 99.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 31, 2025 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 26, 2025, among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and includes any successor Company thereto (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchas |
|
| March 31, 2025 |
Exhibit 10.18 Kadimastem Ltd. Registrar of Companies Number: 514192558 (the “Company”) Dated: 09/12/2021 Company: 6409 To: The National Authority for Technological Innovation RE: Letter of Commitment and Notice of Commencement of an Approved Program 1. We hereby sign this Letter of Commitment and Notice of Commencement of the Approved Program (hereinafter: the "Letter of Commitment") in relation t |
|
| March 31, 2025 |
COMMON SHARES PURCHASE AGREEMENT Exhibit 99.3 COMMON SHARES PURCHASE AGREEMENT This COMMON SHARES PURCHASE AGREEMENT is made and entered into as of March 28, 2025 (this “Agreement”), by and between Alpha Capital Anstalt, a Liechtenstein Anstalt (the “Investor”), and NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”). RECITALS WHEREAS, the parties desire that, upon the terms and subjec |
|
| March 10, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission file number: 001-39957 NLS PHARMACEUTICS |
|
| March 10, 2025 |
NLS Pharmaceutics CEO Issues Letter to Shareholders Exhibit 99.1 NLS Pharmaceutics CEO Issues Letter to Shareholders ZÜRICH, Switzerland, March 10, 2025 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders. Dear Shareholders, We are thrilled to share the significant progress and strate |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices |
|
| March 3, 2025 |
RESEARCH AND LICENSE AGREEMENT Exhibit 10.8 RESEARCH AND LICENSE AGREEMENT This Research and License Agreement (“Agreement”) is made this 22nd day of January, 2015 (the “Effective Date”), by and between: RAMOT AT TEL AVIV UNIVERSITY LTD. of P.O.B. 39296, Tel-Aviv 6139001, Israel (“Ramot”), on the first part; and KADIMASTEM LTD., of 7 Sapir St., Weizmann Science Park, Ness-Ziona 74140, Israel; (the “Company”), of the second part |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.5 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
As filed with the U.S. Securities and Exchange Commission on February 28, 2025. As filed with the U.S. Securities and Exchange Commission on February 28, 2025. Registration No. 333-284075 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdicti |
|
| March 3, 2025 |
BIRDF FUNDED COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT Exhibit 10.9 Execution Version BIRDF FUNDED COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT THIS BIRDF FUNDED COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) dated as of April 29, 2023 (the “Effective Date”), is entered into by and between Kadimastem Ltd., a public company formed and registered under the laws of the State of Israel (“Kadimastem”) with a principal address located at |
|
| March 3, 2025 |
Exhibit 10.11 [PARENT], [ADDRESS] Confidential [Director] [Company] [Address] [Company] [Address] Zurich, [Date] 2025 Re: Indemnification Agreement Dear [Director], In consideration of your prior and continuing service in your capacity as member of the board of directors (the “Board”) of (i) [Company], [Address], with company register no. CHE-[…], (ii) [Company], [Address], with company register n |
|
| March 3, 2025 |
Exhibit 4.2 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT by and between NLS PHARMACEUTICS LTD., and VSTOCK TRANSFER, LLC, as the Rights Agent Dated as of November 4, 2024 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated November 4, 2024, is by and between, NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“NLS”), and VStock Transfer, LLC, a California limited liability co |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.8 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.7 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 4.1 PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Warrant Shares: [] Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT, issued in the form of uncertificated securities (Wertrechte) pursuant to article 973c of the Swiss Code of Obligations (the “Warrant”), certifies that, for value received, [] or its assigns (the “Holder”) |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.6 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
CONSENT TO BE NAMED AS DIRECTOR Exhibit 99.4 CONSENT TO BE NAMED AS DIRECTOR In connection with the Registration Statement on Form F-4 (including any and all amendments, including post-effective amendments, or supplements thereto, the “Registration Statement”) of NLS Pharmaceutics Ltd. (the “Company”), the undersigned hereby consents to being named and described in the Registration Statement filed with the U.S. Securities and Ex |
|
| March 3, 2025 |
Exhibit 10.10 AMENDED AND RESTATED RESEARCH AND LICENCE AGREEMENT This Amended and Restated Research and Licence Agreement (“Agreement”) is entered into on 7 May 2013, and is effective as of 29 October 2009 (“the Effective Date”) Between HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. a company duly incorporated and existing under the laws of the State of Israel of P.O. Box 12000 Jerusalem |
|
| March 3, 2025 |
Exhibit 10.7 FEASIBILITY STUDY AGREEMENT THIS FEASIBILITY STUDY AGREEMENT (the “Agreement”) is entered into effect on September 9, 2018 (the “Effective Date”) PARTIES 1. Kadimastem Ltd., a public company registered under the laws of Israel, with offices at 7 Sapir St., Weizmann Science Park, Ness-Ziona 74140, Israel (“Kadimastem”) 2. Australian Foundation for Diabetes Research ACN 97 097 263 824 ( |
|
| February 27, 2025 |
Exhibit 99.1 NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform Zürich, Switzerland – February 27, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), in collaboration with Aexon Labs Inc. ( “Aexon Labs”), is pleased to announce new preclinical findings on AEX-2, rein |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| February 25, 2025 |
Exhibit 99.1 Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long Immune Suppression ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL, February 25, 2025. NLS Pharmaceutics Ltd. (Nasdaq: NLSP”) (“NLS”) and Kadimast |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| February 25, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 (Report No. 2) Commission file number: 001-39957 |
|
| February 14, 2025 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares, par value CHF 0.02 per share, of NLS Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offi |
|
| February 10, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission file number: 001-39957 NLS PHARMACEUT |
|
| February 10, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) NLS Pharmaceutics Ltd. |
|
| February 10, 2025 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies ● Revolutionizing Diabetes Treatment: Introduction of cutting-edge, multi-targeted innovation to transform diabetes care. ● Diabetes more than just a Metabolic Disorder: Diabetes is a multi-systemic disease impacting the central nervous system (CNS), immune function, and cellula |
|
| February 10, 2025 |
As filed with the Securities and Exchange Commission on February 10, 2025 As filed with the Securities and Exchange Commission on February 10, 2025 Registration No. |
|
| February 5, 2025 |
As filed with the Securities and Exchange Commission on February 4, 2025 As filed with the Securities and Exchange Commission on February 4, 2025 Registration No. |
|
| February 5, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) NLS Pharmaceutics Ltd. |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 8) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 31, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 7) Commission file number: 001-39957 |
|
| January 31, 2025 |
TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Exhibit 99.1 AMENDMENT TO THE AGREEMENT OF MERGER AND PLAN OF REORGANIZATION This Amendment, dated January 30, 2025 (this “Amendment”) to the Agreement of Merger and Plan of Reorganization dated November 4, 2024 (the “Agreement”) between Kadimastem Ltd., an Israeli publicly traded company limited by shares (“Kadimastem”), NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzer |
|
| January 31, 2025 |
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics Exhibit 99.1 Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL — January 31, 2025 / NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (“Kadimastem”) (TASE |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 7) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 6) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 30, 2025 |
Exhibit 99.1 NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting Zurich, Switzerland – January 30, 2025 – NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, is pleased to announce the |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 5) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 28, 2025 |
Exhibit 99.1 NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence ● Centers for Disease Control and Prevention (the “CDC”) reported 105,007 drug overdose deaths - with 90% involving synthetic opioids like fentanyl ● Mazindol ER potentially offers a non-opioid alternative, addressing the underlying neurochemical imbalances associate |
|
| January 28, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 5) Commission file number: 001-39957 |
|
| January 16, 2025 |
Exhibit 99.1 Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS Kadimastem Approaches Final Steps for Securing Merger Completion ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL— January 16th 2025 — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 16, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 4) Commission file number: 001-39957 |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| January 8, 2025 |
Exhibit 99.1 NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025 ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL— January 8, 2025 — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a |
|
| January 8, 2025 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 (Report No. 2) Commission file number: 001-39957 |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of January 2025 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offic |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 7) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 30, 2024 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 7) Commission file number: 001-39957 |
|
| December 30, 2024 |
Exhibit 99.1 NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and a focus on advancing its allogeneic cell therapy platform ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL, December 30 |
|
| December 30, 2024 |
As filed with the U.S. Securities and Exchange Commission on December 27, 2024. As filed with the U.S. Securities and Exchange Commission on December 27, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction of incorporation or or |
|
| December 30, 2024 |
Consent of Moore Financial Consulting Exhibit 99.5 Letter of consent December 2024 23/12/2024 Consent of Moore Financial Consulting We hereby consent to the use of our opinion letter dated December 19, 2024 to Kadimastem Ltd. (“Kadimastem”) included as an Annex to the Proxy Statement/Prospectus, which forms a part of the Registration Statement of Kadimastem on Form F-4 relating to the proposed merger of Kadimastem and NLS Pharmaceutic |
|
| December 30, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-4 (Form Type) NLS Pharmaceutics Ltd. |
|
| December 23, 2024 |
Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 23 December 2024 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invi |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 6) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 19, 2024 |
Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 16 December 2024 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invi |
|
| December 19, 2024 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment ● This submission comes after successful INTERACT meeting with the FDA earlier this year. ● NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025 ZURICH, SWITZERLAND an |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 5) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 4) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland ( |
|
| December 19, 2024 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 5) Commission file number: 001-39957 |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 (Report No. 4) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 17, 2024 |
Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 16 December 2024 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invi |
|
| December 11, 2024 |
Exhibit 99.1 NLS Pharmaceutics CEO Issues Letter to Shareholders Zürich, Switzerland, December 11, 2024 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 11, 2024 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 3) Commission file number: 001-39957 |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 6) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of princip |
|
| December 4, 2024 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 4, 2024, among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and includes any successor Company thereto (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purch |
|
| December 4, 2024 |
Exhibit 99.3 NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at an Approximate 15% Premium to the Market ZURICH, SWITZERLAND / ACCESSWIRE / December 4, 2024 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2024 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offi |
|
| December 3, 2024 |
Exhibit 99.1 NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders Zürich, Switzerland, December 3, 2024 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the potential of its dual |
|
| November 25, 2024 |
NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland November 25, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: NLS Pharmaceutics Ltd. (CIK: 0001783036) Registration Statement on Form F-3 (File No. 333-282788) (the “Registration Statement”) Request for Accelera |
|
| November 21, 2024 |
NLSP / NLS Pharmaceutics AG / Hafner Ronald - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0221253-13ga2hafnernls.htm AMENDMENT NO. 2 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) (Rule 13d-102) Under the Securities Exchange Act of 1934 NLS Pharmaceutics Ltd. (Name of Issuer) Common Shares (Title of Class of Securities) H57830103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statem |
|
| November 18, 2024 |
Exhibit 99.1 NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders Zürich, Switzerland, November 18, 2024 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovativ |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 7) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 18, 2024 |
NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland November 18, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Lauren Hamill and Joe McCann Re: NLS Pharmaceutics Ltd. Registration Statement on Form F-3 Filed October 23, 2024 File No. 333-282788 Dear Ms. Hamill and Mr. McCann: The p |
|
| November 18, 2024 |
As filed with the Securities and Exchange Commission on November 18, 2024 As filed with the Securities and Exchange Commission on November 18, 2024 Registration No. |
|
| November 15, 2024 |
Exhibit 99.1 STATUTEN ARTICLES OF ASSOCIATION der of NLS Pharmaceutics AG NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics SA NLS Pharmaceutics Ltd NLS Pharmaceutics Ltd (die “Gesellschaft”) (the “Company”) I. Firma, Sitz, Dauer und Zweck der Gesellschaft I. Name, Domicile, Duration and Purpose of the Company Art. 1 - Firma, Sitz, Dauer Art. 1 - Name, Domicile, Duration Unter der Firma |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 6) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 14, 2024 |
NLSP / NLS Pharmaceutics AG / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NLS Pharmaceuticals Ltd. (Name of Issuer) Common Shares, par value CHF 0.02 per share (Title of Class of Securities) H57830137 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appro |
|
| November 14, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares, par value CHF 0.02 per share, of NLS Pharmaceuticals Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to |
|
| November 14, 2024 |
NLSP / NLS Pharmaceutics AG / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-nlsp093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NLS PHARMACEUTICS LTD. (Name of Issuer) Common shares, nominal value CHF 0.02 per share (Title of Class of Securities) H57830137 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 12, 2024 |
Exhibit 99.4 Kost Forer Gabbay & Kasierer 144A Derech Menachem Begin Tel Aviv 6492102 Tel.: +972-3-6232525 Fax: +972-3-5622555 ey.com November 11, 2024 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following registration statements: (1) Registration Statement (Form F-3 No. 333-262489) of NLS Pharmaceutics Ltd. (2) Registration Statemen |
|
| November 12, 2024 |
UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS The following information and all other information contained in these Unaudited Pro Forma Combined Financial Statements reflects a notice of a reverse split with the commercial registry of the Canton of Zurich, Switzerland, on September 27, 2024 that became effective in Switzerland on September 27, 2024. The reverse stock split was at |
|
| November 12, 2024 |
Kadimastem Ltd. Financial Statements as of December 31, 2023 Table of Contents Exhibit 99.1 Kadimastem Ltd. Financial Statements as of December 31, 2023 Table of Contents Page Report of Independent Registered Public Accounting Firm 2 Statements of Financial Position 3 Statements of Profit or Loss and Other Comprehensive Income 4 Statements of Changes in Equity 5-7 Statements of Cash Flows 8-9 Notes to the Financial Statements 10-66 - - - - - - - - - - - - - - - - 1 Kost Fore |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 5) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 12, 2024 |
Kadimastem Ltd. Interim Financial Statements as of June 30, 2024 Table of Contents Exhibit 99.2 Kadimastem Ltd. Interim Financial Statements as of June 30, 2024 Unaudited Table of Contents Page Statements of Financial Position 2 Statements of Profit or Loss and Other Comprehensive Income 3 Statements of Changes in Equity 4-6 Statements of Cash Flows 7-8 Notes to the Financial Statements 9-16 KADIMASTEM LTD. STATEMENTS OF FINANCIAL POSITION June 30, December 31, 2024 2023 2023 Un |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 (Report No. 3) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 6, 2024 |
Exhibit 99.1 Category: Notifications issued to company members Sub-category: Invitation to the General Meeting Publication date: SHAB 18.10.2024 Publicly viewable until: 18.12.2024 Publication number: UP04-0000006582 Publishing entity Wenger Vieli AG, Dufourstrasse 56, 8008 Zürich Invitation to the extraordinary general meeting NLS Pharmaceutics AG Organisation concerned: NLS Pharmaceutics AG CHE- |
|
| November 5, 2024 |
Exhibit 99.1 AGREEMENT OF MERGER AND PLAN OF REORGANIZATION BY AND AMONG NLS Pharmaceutics LTD. NLS PHARMACEUTICS (ISRAEL) LTD. and KADIMASTEM LTD. DATED AS OF NOVEMBER 4, 2024 CONTENTS Page Article I THE MERGER 1.1 The Merger 2 1.2 Closing 2 1.3 Effective Time 2 1.4 Articles of Association 3 1.5 Effects of the Merger 3 1.6 Officers and Directors 3 Article II EFFECTS OF MERGER ON SHARE CAPITAL; EX |
|
| November 5, 2024 |
Exhibit 99.2 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT by and between NLS PHARMACEUTICS LTD., and VSTOCK TRANSFER, LLC, as the Rights Agent Dated as of , 2024 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated , 2024, is by and between, NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“NLS”), and VStock Transfer, LLC, a California limited liability company, as Rights Ag |
|
| November 5, 2024 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission file number: 001-39957 |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| November 5, 2024 |
Exhibit 99.3 VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”), dated as of , 2024 (the “Effective Date”), by and among NLS Pharmaceutics Ltd. (the “Company”), a corporation incorporated under the laws of Switzerland, and certain the shareholders of the Company listed on Schedule A hereto (each, a “Shareholder” and, collectively, the “Shareholders”). RECITALS WHEREA |
|
| November 4, 2024 |
EX-99.1 2 tm2427411d6ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the equity securities of NLS Pharmaceutics Ltd. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulg |
|
| November 4, 2024 |
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement Exhibit 99.1 NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement Zurich, Switzerland and Ness Ziona, Israel- November 4, 2024 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (“NLS”), a biopharmaceutical company, and Kadimastem Ltd. (TASE: KDST.TA”) (“Kadimastem”), a clinical-stage cell therapy company developing and manufacturing “off-the-shelf” allogeneic cell products for the treat |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offi |
|
| November 4, 2024 |
NLSP / NLS Pharmaceutics AG / Grisard Felix - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0219947-13ga1felixnlsphar.htm AMENDMENT NO. 1 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) (Rule 13d-102) Under the Securities Exchange Act of 1934 NLS Pharmaceutics Ltd. (Name of Issuer) Common Shares (Title of Class of Securities) H57830103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Sta |
|
| November 4, 2024 |
Filed by NLS Pharmaceutics Ltd. pursuant to Rule 425 under the Securities Act of 1933, as amended Subject Company: Kadimastem Ltd. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2024 Commission file number: 001-39957 NLS PHARMACEUT |
|
| November 4, 2024 |
NLSP / NLS Pharmaceutics AG / YA II PN, Ltd. - SC 13G/A Passive Investment SC 13G/A 1 tm2427411d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO SCHEDULE 13G Under the Securities Exchange Act of 1934 NLS PHARMACEUTICS LTD. (Name of Issuer) Common Shares, par value CHF 0.02 per share (Title of Class of Securities) H57830103 (CUSIP Number) September 30, 2024 (Date of Event, which Requires Filing of this Stateme |
|
| October 28, 2024 |
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements Exhibit 99.1 NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements ZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system diso |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 9) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 23, 2024 |
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 23, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) NLS Pharmaceutics Ltd. |
|
| October 23, 2024 |
As filed with the Securities and Exchange Commission on October 23, 2024 As filed with the Securities and Exchange Commission on October 23, 2024 Registration No. |
|
| October 22, 2024 |
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence Exhibit 99.2 NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence Zurich, Switzerland - October 21 2024 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is pleased to announce that i |
|
| October 22, 2024 |
Exhibit 10.1 DEBT FORGIVENESS AGREEMENT THIS DEBT FORGIVENESS AGREEMENT (this “Agreement”) is made and entered into and effective as of this []th day of [], 2024 (the “Effective Date”), by and between NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (“the Company”), and [] (the “Lender”). WHEREAS, on the terms and subject to the conditions set forth in this Agreemen |
|
| October 22, 2024 |
STATUTEN NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics Ltd (die “Gesellschaft”) Exhibit 99.1 STATUTEN der NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics Ltd (die “Gesellschaft”) ARTICLES OF ASSOCIATION of NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics Ltd (the “Company”) I. Firma, Sitz, Dauer und Zweck der Gesellschaft Art. 1 - Firma, Sitz, Dauer I. Name, Domicile, Duration and Purpose of the Company Art. 1 - Name, Domicile, Duration Unter der Firma |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 8) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 18, 2024 |
Exhibit 99.1 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023 AND FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page Interim Condensed Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 1 Unaudited Interim Condensed Statements of Operations an |
|
| October 18, 2024 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis should be read in conjunction with our unaudited interim condensed financial statements and related notes as of and for the six months ended June 30, 2024, included as Exhibit 99.1 to this Report on Form 6-K. This discussion and other parts of the interim report |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 7) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 6) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 15, 2024 |
Exhibit 99.1 NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules ZURICH, SWITZERLAND / ACCESSWIRE / October 15, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with ra |
|
| October 15, 2024 |
NLSP / NLS Pharmaceutics AG / ALPHA CAPITAL ANSTALT - SCHEDULE 13G Passive Investment SC 13G 1 ea0217643-13galphanlsphar.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) NLS PHARMACEUTICS LTD. (Name of Issuer) COMMON SHARES, PAR VALUE CHF 0.02 PER SHARE (Title of Class of Securities) H57830103 (CUSIP Number) October 10, 2024 (DATE OF EVENT WHICH REQUIRES FILING OF THIS ST |
|
| October 11, 2024 |
REGISTRATION RIGHTS AGREEMENT (Debt Satisfaction and Equity) Exhibit 99.7 REGISTRATION RIGHTS AGREEMENT (Debt Satisfaction and Equity) REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 8, 2024, by and among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland, with headquarters located at The Circle 6, 8058 Zurich, Switzerland (the “Company”), and the investors listed on the Schedule of Purchasers attached her |
|
| October 11, 2024 |
AMENDMENT TO THE NLS PHARMACEUTICS LTD. COMMON SHARE PURCHASE WARRANTS October [ ], 2024 Exhibit 99.4 AMENDMENT TO THE NLS PHARMACEUTICS LTD. COMMON SHARE PURCHASE WARRANTS October [ ], 2024 This Amendment No. 1, dated October [ ], 2024, (the “Effective Date”), to the following common share purchase warrants (the “Amendment”), issued by the Company, and issued on or about [DATE], to [HOLDER NAME] (the “Investor”) to purchase [NUMBER OF SHARES] ([ ] pre-September 2024 share split) comm |
|
| October 11, 2024 |
PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 99.5 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 11, 2024 |
Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 9, 2024, among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and includes any successor Company thereto (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purcha |
|
| October 11, 2024 |
Exhibit 99.8 SECURITIES EXCHANGE AGREEMENT This Securities Exchange Agreement (this “Agreement”) is dated as of October [*], 2024, among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and includes any successor Company thereto (the “Company”), and each holder identified on the signature pages hereto (each, including its successors and permitted assigns, a “Holder” |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 5) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 11, 2024 |
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 99.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 11, 2024 |
Exhibit 99.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 9, 2024, among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland and includes any successor Company thereto (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purcha |
|
| October 11, 2024 |
Exhibit 99.6 REGISTRATION RIGHTS AGREEMENT (Equity) REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 7, 2024, by and among NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland, with headquarters located at The Circle 6, 8058 Zurich, Switzerland (the “Company”), and the investors listed on the Schedule of Purchasers attached hereto (each, a “Purchase |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of October 2024 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offic |
|
| September 25, 2024 |
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split Exhibit 99.2 NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split ZURICH, SWITZERLAND / ACCESSWIRE / September 25, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principa |
|
| September 25, 2024 |
STATUTEN NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics Ltd (die “Gesellschaft”) Exhibit 99.1 STATUTEN der NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics Ltd (die “Gesellschaft”) ARTICLES OF ASSOCIATION of NLS Pharmaceutics AG NLS Pharmaceutics SA NLS Pharmaceutics Ltd (the “Company”) I. Firma, Sitz, Dauer und Zweck der Gesellschaft Art. 1 - Firma, Sitz, Dauer I. Name, Domicile, Duration and Purpose of the Company Art. 1 - Name, Domicile, Duration Unter der Firma |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September 2024 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principa |
|
| September 17, 2024 |
AMENDMENT TO THE NLS PHARMACEUTICS LTD. COMMON STOCK PURCHASE WARRANTS September 16, 2024 Exhibit 10.1 AMENDMENT TO THE NLS PHARMACEUTICS LTD. COMMON STOCK PURCHASE WARRANTS September 16, 2024 This Amendment No. 1, dated September 16, 2024 (the "Effective Date"), to each of the following four common stock purchase warrants (the “Amendment”), issued by NLS Pharmaceuticals Ltd, a Swiss corporation (the “Company”), and each issued on or about (a) January 29, 2021, to Armistice Capital Mas |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 (Report No. 2) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principa |
|
| September 17, 2024 |
PRE-FUNDED COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive off |
|
| September 13, 2024 |
Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 10 September 2024 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to inv |
|
| August 27, 2024 |
As filed with the Securities and Exchange Commission on August 27, 2024 As filed with the Securities and Exchange Commission on August 27, 2024 Registration No. |
|
| August 27, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) NLS Pharmaceutics Ltd. |
|
| August 27, 2024 |
NLS Pharmaceutics Ltd - Kadimastem Ltd BINDING TERM SHEET Exhibit 10.21 NLS Pharmaceutics Ltd - Kadimastem Ltd BINDING TERM SHEET This binding term sheet (this “Term Sheet”) is entered into by and between NLS Pharmaceutics Ltd (the “Company” or “NLSP”) and Kadimastem Ltd (“Kadimastem”). Subject to the limitations set forth below, the parties hereto, intending to be legally bound hereby as provided herein, and each having received good and valuable consid |
|
| August 26, 2024 |
[voting instructions and appendices follow] EX-99.1 2 ea021235301ex99-1nlspharma.htm NOTICES OF MEETING AND PROXY CARD FOR THE EXTRAORDINARY SHAREHOLDERS' MEETINGS TO BE HELD ON SEPTEMBER 18, 2024 Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, 26 August 2024 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 (Report No. 3) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal e |
|
| August 15, 2024 |
Exhibit 16.1 August 15, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by NLS Pharmaceutics Ltd. pursuant to Item 304(a)(1) of Regulation S-K (copy attached), which we understand will be filed with the Securities and Exchange Commission on Form 6-K of NLS Pharmaceutics Ltd. dated August 15, 2024. We agree with the sta |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2024 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6, CH-8058 Zurich, Switzerland (Address of princip |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive office |
|
| July 30, 2024 |
Exhibit 99.1 NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem’s allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support for the transaction from s |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| July 1, 2024 |
COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 1, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 28, 2024, between NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, sub |
|
| July 1, 2024 |
SERIES A PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 1, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-262489 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 11, 2022) 3,277,750 Common Shares We are offering 3,277,750 of our common shares, 0.02 CHF par value per share, or the Shares, pursuant to this prospectus supplement and the accompanying prospectus. The offering price of each Share and accompanying Private Placement Warrant (as defined |
|
| July 1, 2024 |
NLS Pharmaceutics AG NLS Pharmaceutics Announces Registered Direct Offering Exhibit 99.1 NLS Pharmaceutics AG NLS Pharmaceutics Announces Registered Direct Offering ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, |
|
| July 1, 2024 |
SERIES B PLACEMENT AGENT COMMON SHARE PURCHASE WARRANT NLS PHARMACEUTICS LTD. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2024 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) |
|
| June 27, 2024 |
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson’s Disease Treatments Exhibit 99.1 NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson’s Disease Treatments Zurich, Switzerland - June 27, 2024 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced preclinical results fr |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 (Report No. 5) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 25, 2024 |
Exhibit 99.1 Nasdaq Panel Grants NLS Pharmaceutics’ Request for Extension to Comply with Continued Listing Requirements Zürich, Switzerland, June 25, 2024 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received notice f |
|
| June 25, 2024 |
[voting instructions and appendices follow] Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, June 25, 2024 Invitation to the Ordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invite you t |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 24, 2024 |
NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland June 24, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: NLS Pharmaceutics Ltd. (CIK: 0001783036) Registration Statement on Form F-1 (File No. 333- 279806) (the “Registration Statement”) Request for Acceleratio |
|
| June 11, 2024 |
Exhibit 99.1 NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA) Zurich, Switzerland - June 11, 2024 - NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, to |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exe |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of June 2024 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) |
|
| June 6, 2024 |
[voting instructions and appendices follow] Exhibit 99.1 To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, June 5, 2024 Invitation to the Ordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “Board of Directors”), with registered office at The Circle 6, 8058 Zurich, Switzerland (the “Company”) is pleased to invite you to |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 (Report No. 5) Commission File Number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exec |
|
| May 30, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024. As filed with the Securities and Exchange Commission on May 29, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NLS Pharmaceutics Ltd. (Exact name of registrant as specified in its charter) Switzerland 3841 Not Applicable (State or other jurisdiction of incorporation or organization) |
|
| May 30, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) NLS Pharmaceutics Ltd. |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2024 (Report No. 4) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exec |
|
| May 28, 2024 |
Exhibit 99.1 NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model ZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system diso |
|
| May 24, 2024 |
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq Exhibit 99.1 NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq ZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous sys |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2024 (Report No. 3) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exec |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2024 (Report No. 2) Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant’s name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal exec |
|
| May 22, 2024 |
ADDENDUM TO THE Loan Agreement November 15, 2023 Exhibit 99.1 ADDENDUM TO THE Loan Agreement “Agreement” of November 15, 2023 between NLS Pharmaceutics AG The Circle 6 8058 Zürich Switzerland “Borrower” and [] [] [] [] “Lender” (Borrower and Lender each a ʺPartyʺ collectively the ʺPartiesʺ) Page 1 of 3 Whereas: A. The Parties entered into a loan agreement with the loan amount of CHF [] and accrued interest thereon (if any) (“Loan Amount”) dated |
|
| May 15, 2024 |
Description of Rights of Each Class of Securities Exhibit 2.1 Description of Rights of Each Class of Securities Type and Class of Securities As of December 31, 2023, NLS Pharmaceutics Ltd., or the Company, had a share capital of CHF 713,435.60 divided into 35,671,780 registered shares with a nominal value of CHF 0.02 each, or the Common Shares. As part of the initial public offering of the Company in February 2021 on the Nasdaq Capital Market, th |
|
| May 15, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Alexander Zwyer, certify that: 1. I have reviewed this annual report on Form 20–F of NLS Pharmaceutics Ltd.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde |
|
| May 15, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2023 (the “Report”) by NLS Pharmaceutics Ltd. (the “Company”), the undersigned, as Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies with the requirem |
|
| May 15, 2024 |
NLS Pharmaceutics Ltd. (the “Company”) CLAWBACK POLICY Effective as of November 8, 2023 Exhibit 97.1 NLS Pharmaceutics Ltd. (the “Company”) CLAWBACK POLICY Effective as of November 8, 2023 Background The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. T |
|
| May 15, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Elena Thyen-Pighin, certify that: 1. I have reviewed this annual report on Form 20–F of NLS Pharmaceutics Ltd.; 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| May 15, 2024 |
[Signature Page to Exclusive License Agreement] Exhibit 4.18 NLS/AEX CONFIDENTIAL EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (the “Definitive Agreement”) is made effective as of March 19, 2024 (the “Effective Date”) by and between Aexon Labs Inc. a Delaware corporation (“Licensor” or “Aexon Labs”), with its principal place of business at 16192 Coastal Hwy, Lewes 19958, DE USA and NLS Pharmaceutics Ltd., a company organized und |
|
| May 15, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2023 (the “Report”) by NLS Pharmaceutics Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, to my knowledge: (1) the Report fully complies with the requ |
